SHANGHAI, 26. Mai 2023 /PRNewswire/ –BioRay Pharmaceutical Co Ltd. (im Folgenden als BioRay bezeichnet) (BioRay) gab bekannt, dass der IND-Antrag (Investigational New Drug) für die klinische Erprobung des firmeneigenen BRY812, eines neuartigen Antikörper-Wirkstoff-Konjugats (ADC), das…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.